Drug
Fulranumab clinical trials
Also written JNJ-42160443 and AMG 403.
How studies write it
Studies that test it under each name
Studies by the year they started
13 studies that test it; most in 2009 (5)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2006 | 1 |
| 2009 | 5 |
| 2010 | 2 |
| 2015 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 13 · Other 0
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (6) · Janssen Research & Development, LLC (5) · Amgen (2)
Studies
Open first, then newest update. How each study uses fulranumab is read from its arms, and is right about nine times in ten.
Testing it · 13
- Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3003CompletedPhase 3Janssen Research & Development, LLCNCT02289716Written as Fulranumab 1 mg
- A Study to Evaluate the Pain Relieving Effects, Safety, and Tolerability of JNJ-42160443 for the Relief of Bladder PainTerminatedPhase 2Johnson & Johnson Pharmaceutical Research & Development, L.L.C.NCT01060254Written as JNJ-42160443
- A Safety and Tolerability Study of JNJ-42160443 in Patients With Moderate to Severe, Chronic Knee Pain From OsteoarthritisTerminatedPhase 2Johnson & Johnson Pharmaceutical Research & Development, L.L.C.NCT01094262Written as JNJ-42160443
- A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Osteoarthritis-related PainTerminatedPhase 2Johnson & Johnson Pharmaceutical Research & Development, L.L.C.NCT00973141Written as JNJ-42160443
- Study of Efficacy, Safety of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3001CompletedPhase 3Janssen Research & Development, LLCNCT02336685Written as Fulranumab 1 mg
- Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3002CompletedPhase 3Janssen Research & Development, LLCNCT02336698Written as Fulranumab 1 mg
- Study of Safety, Efficacy of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3007CompletedPhase 3Janssen Research & Development, LLCNCT02301234Written as Fulranumab 1 mg
- A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Low Back PainTerminatedPhase 2Johnson & Johnson Pharmaceutical Research & Development, L.L.C.NCT00973024Written as JNJ-42160443 3 mg
- A Study of Effectiveness and Safety of JNJ-42160443 in Patients With Diabetic Painful NeuropathyTerminatedPhase 2Johnson & Johnson Pharmaceutical Research & Development, L.L.C.NCT00993018Written as JNJ-42160443 (1 mg)
- A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Patients With Neuropathic Pain (Postherpetic Neuralgia and Post-traumatic Neuralgia)TerminatedPhase 2Johnson & Johnson Pharmaceutical Research & Development, L.L.C.NCT00964990Written as JNJ-42160443
- A Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Cancer-related PainCompletedPhase 2Janssen Research & Development, LLCNCT00929188Written as JNJ-42160443
- A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of AMG 403 in Healthy SubjectCompletedPhase 1AmgenNCT02348879Written as AMG 403
- A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 403 in Subjects With Osteoarthritis Knee PainCompletedPhase 1AmgenNCT02318407Written as AMG 403
Codes
What other systems call fulranumab · ClinicalTrials.gg INT000085
- MeSH (NLM) C000592179fulranumabOne source NLM
- UNII (FDA) 0E986JU40IFULRANUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q5508378FulranumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C84838FulranumabOne source FDA
- DrugBank DB12102One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000592179 | fulranumab | One source NLM |
| UNII (FDA) | 0E986JU40I | FULRANUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q5508378 | Fulranumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C84838 | Fulranumab | One source FDA |
| DrugBank | DB12102 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.